Overview Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. We are currently focusing our development efforts on picoplatin, a new generation platinum chemotherapy agent with the potential to become a platform product addressing multiple indications, combinations and formulations. Picoplatin has an improved safety profile compared to existing platinum-based chemotherapeutics. It was designed to overcome platinum resistance associated with chemotherapy in solid tumors and delay time to relapse. We are studying picoplatin in multiple cancer indications, combinations and formulations. Our business strategy is to form partnerships to support and expand our clinical programs and commercial opportunities and to build a diverse portfolio of oncology product candidates. As part of this strategy, we are collaborating with The Scripps Research Institute on the discovery of novel, small-molecule, multi-targeted protein kinase inhibitors as therapeutic agents to treat cancer. Poniard is headquartered in South San Francisco. We are traded on the NASDAQ Global Market under the symbol PARD. We invite you to discover what is new at Poniard Pharmaceuticals.